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Abstract 26 
A retrospective study was conducted in a large sample of acutely hospitalized older patients 27 
who underwent therapeutic drug monitoring during levofloxacin treatment. The aim was to assess 28 
the population pharmacokinetics (popPK) and pharmacodynamics of levofloxacin among older 29 
patients. 30 
PopPK and  Monte Carlo simulation were performed for defining the permissible doses in older 31 
patients according to various degrees of renal function. CART analysis was used to detect the cut-32 
off AUC24h/MIC ratio that best correlated with clinical outcome. Probability of target attainment 33 
(PTA) of this value was calculated against different pathogens. 168 patients were included, and 330 34 
trough and 239 peak concentrations were used for the popPK analysis. Creatinine clearance was the 35 
only covariate that improved the model fit (Levofloxacin CL=0.399+0.051∙CrCLCKD-EPI). Drug 36 
doses ranged between 500 mg every 48h and 500 mg every 12h in relation to different renal 37 
function. The identified cut-off AUC24h/MIC ratio (≥ 95.7) was the only covariate that correlated 38 
with favorable clinical outcome at multivariate regression analysis (OR 20.85; 95% CI 1.56–39 
186.73).  PTAs were optimal (>80%) against E. coli and H. influenzae, borderline against S. aureus, 40 
and suboptimal against P. aeruginosa. Levofloxacin doses defined in our study may be effective for 41 
the treatment of infections due to bacterial pathogens with an MIC ≤ 0.5 mg/L in older patients with 42 
various degrees of renal function, while minimizing the toxicity risk. Conversely, the addition of 43 
another active antimicrobial should be considered whenever treating infections caused by less 44 
susceptible pathogens. 45 
 46 
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Introduction 51 
Levofloxacin is a fluoroquinolone antibiotic with one of the broadest spectra of activity, 52 
encompassing both Gram-negative and Gram-positive organisms, atypical and anaerobic bacteria 53 
(1). Accordingly, it has been used for many years for the treatment of a variety of infections, such 54 
as community-acquired pneumonia, skin and soft tissues infections, urinary tract infections, acute 55 
exacerbation of chronic bronchitis and sinusitis (2, 3).   56 
Levofloxacin is a moderately lipophilic drug, which is mainly renally eliminated as an 57 
unchanged moiety. A linear relationship between drug clearance (CL) and creatinine clearance 58 
(CrCL) has been demonstrated (4). From a pharmacodynamic  point of view, it has been shown that 59 
the most relevant predictor of  fluoroquinolone efficacy in clinical settings is the 24-hour area under 60 
the concentration-time curve (AUC24h)/minimum inhibitory concentration (MIC) ratio. Different 61 
AUC24h/MIC ratios have been proposed as optimal targets according to the invading pathogen. 62 
Although an AUC24h/MIC ratio of 25-30 may suffice for infections due to S. pneumoniae (5), values 63 
of 100-125 have been recommended for efficacy against those due to Gram-negative pathogens (6, 64 
7). Interestingly, an AUC24h/MIC target of ≥ 87 was associated with microbiological eradication of 65 
both Gram-positives and Gram-negatives among 47 patients who were treated with levofloxacin for 66 
nosocomial pneumonia (8). However, it should be noticed that in this study levofloxacin was 67 
combined with other agents in those patients infected with Pseudomonas aeruginosa (ceftazidime 68 
or piperacillin/tazobactam) or with  methicillin-resistant Staphylococcus aureus (vancomycin) (8). 69 
Similarly, combination therapy was also present in the retrospective analysis by Schentag et al. (7).     70 
Fluoroquinolones are among the most frequently used antimicrobials for the treatment of 71 
community acquired infections, which account for a significant amount of emergency visits and 72 
hospitalizations among older adults. Older patients may be at increased risk of adverse drug 73 
reactions (ADRs), mainly because of the pathophysiological changes associated with ageing 74 
processes and/or of polypharmacy (9). High frequency of tendinopathy and of tendon ruptures in 75 
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older patients were associated with ageing, impairment of renal function and corticosteroid co-76 
administration (10, 11).   77 
Accordingly, since levofloxacin toxicity is dose dependent (12), from a safety perspective, 78 
dosage adjustments in older patients with varying degrees of renal impairment should be warranted 79 
in order to avoid drug-related toxicity (13, 14).  80 
The primary aim of this study was to describe the population pharmacokinetics and 81 
pharmacodynamics of high dose levofloxacin in a large sample of acutely hospitalized older 82 
patients in order to estimate the permissible doses that would grant safe and effective exposure in 83 
older patients with various degrees of renal function.        84 
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Materials and Methods  85 
Study design 86 
This was a retrospective study conducted between May 2007 and December 2012 among 87 
older patients aged ≥ 65 years, who were admitted at the 1st Division of Internal Medicine of the 88 
Santa Maria della Misericordia University Hospital of Udine, Udine, Italy, and who underwent 89 
therapeutic drug monitoring (TDM) of levofloxacin at the Institute of Clinical Pharmacology of the 90 
same hospital. The study was approved by the Regional Ethics Committee. Informed written 91 
consent was waived according to the retrospective and observational nature of the study.    92 
Patients received levofloxacin because of documented or suspected bacterial infection. The 93 
use of additional antimicrobial agents was permitted and at the discretion of treating physician 94 
(ceftazidime, piperacillin/tazobactam or meropenem for suspected and/or proven Gram-negative 95 
infections; vancomycin or teicoplanin for suspected and/or proven MRSA infections).   96 
The dosage of levofloxacin was initially chosen by the attending physician and subsequently 97 
adjusted on the basis of TDM-guided clinical pharmacological advices that were made promptly 98 
available in the hospital intranet.  TDM of levofloxacin is routinely performed at our hospital, with 99 
target concentrations of 1-3 mg/L for trough and of 6-9 mg/L for peak (which was collected 2 hours 100 
after oral administration or 1.5 hours after i.v. administration), respectively. These concentrations 101 
correspond to AUC24h values between 50 and 160 mg∙h/L,  that are the range of exposures normally 102 
observed with the standard high dose of 500 mg every 12h (that is licensed in Italy) in subjects with 103 
normal renal function (7, 15-17). This TDM-guided approach, by maintaining exposure within the 104 
expected normal range, is finalized to prevent theoretical overexposure (arbitrarily defined as 105 
AUC24h > 160 mg∙h/L) and may concur to minimize the risk of exposure dependent toxicity in older 106 
patients, definitely the population at greater risk of toxicity during levofloxacin therapy (11).  107 
The following demographic and clinical data were retrieved from each patient's medical 108 
record: age, gender, weight, height, type and site of infection, bacterial clinical isolate (whenever 109 
available) with MIC of levofloxacin, underlying disease(s), serum creatinine, levofloxacin dose, 110 
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route of administration and TDM data, and co-treatment with any other drug. Baseline and end of 111 
therapy C-reactive protein (CRP) were also collected.  Creatinine clearance was estimated by means 112 
of the Chronic Kidney Disease Epidemiology (CKD-EPI) formula (CrCLCKD-EPI) (18).  113 
Blood samples for TDM were collected at least 48 hours from starting levofloxacin. 114 
Levofloxacin concentrations were analyzed by means of a validated high performance liquid 115 
chromatography (HPLC) method with UV detection, as previously described (4). Precision and 116 
accuracy were assessed by performing replicate analysis of quality control samples against 117 
calibration standards. Intra- and inter-assay coefficients of variation were always less than 10%. 118 
The lower limit of detection was 0.1 mg/L.  119 
 120 
Assessment of clinical outcome 121 
Clinical outcomes were defined as cured, improved, unchanged or failed according to 122 
treatment response assessed at end of therapy by the attending physician.  A patient was classified 123 
as cured if signs and symptoms of infection disappeared at the end of therapy, as improved in case 124 
of partial clinical response associated with significant decrease in CRP values from baseline, as 125 
unchanged or failed  in case of absence of  clinical response at the end of therapy. Patients cured 126 
and improved were considered to have a successful clinical outcome. 127 
 128 
Population pharmacokinetic modeling 129 
One and two-compartment models were developed and fitted using the non-parametric 130 
adaptive grid (NPAG) approach included in the Pmetrics package for R (Los Angeles, CA, USA) 131 
(19).  The base-weighting scheme was developed by use of a polynomial function that relates drug 132 
concentration to the standard deviation (SD) of the observations, using the between-day assay 133 
variability data. Maximum a posteriori probability (MAP)-Bayesian parameter estimates for 134 
levofloxacin were determined for each patient in the dataset, and were used for describing the 135 
pharmacokinetic parameters (ka, kcp, kpc, CL, Vd, Fos, Tlag) for each patient in the population. 136 
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Firstly, we developed a basic model without covariates by using the building dataset, which 137 
was parameterized only for clearance (CL) and for volume of distribution (Vd). Subsequently, we 138 
tested covariates that were deemed clinically relevant. Only those covariates that significantly 139 
increased the log-likelihood value of the covariate model (i.e. twice the difference in log-likelihood 140 
value for the covariate versus the base model with the appropriate degrees of freedom assessed 141 
against a χ2 distribution) were retained for further analysis. 142 
The model performance was further evaluated by assessing the goodness-of-fit of the 143 
observed-predicted plot, the coefficient of determination of the linear regression of the observed-144 
predicted values and the OFV (Objective Function Value) of each run. Additionally, also a visual 145 
predictive check (VPC) and normalized prediction distribution errors (NPDEs) were determined. 146 
The VPC compares the observed concentrations overlaid with model-predicted concentration-time 147 
profiles; 95% of observed concentrations should reside within the 95% confidence interval (CI) 148 
derived from model predictions. NPDEs provide a quantitative assessment of the final model and 149 
are considered a better evaluation tool than a plot of weighted residuals, especially when dealing 150 
with models with covariates (20). NPDEs should be normally distributed when the model is 151 
appropriately fitted.   152 
 153 
Monte Carlo simulation for estimation of levofloxacin doses predicting optimal target drug 154 
exposure in older patients with various degrees of renal function  155 
One thousand-subject Monte Carlo simulations were conducted using Pmetrics to estimate 156 
the AUC24h achievable with various candidate regimens of levofloxacin (125 mg every 48h, 250 mg 157 
every 48h, 250 mg daily, 500 mg every 48h, 750 mg every 48h, 500 mg daily, 750 mg daily and 158 
500 mg every 12h) for different levels of renal function (0-19, 20-39, 40-59, 60-79 and > 80 159 
mL/min/1.73 m2).   160 
In order to define the permissible levofloxacin doses in the study population, we considered 161 
as desirable in this population the achievement of the exposure range that was observed in healthy 162 
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volunteers with normal renal function with the standard high dose of 500 mg every 12h (AUC24h of 163 
50-160 mg∙h/L) (14-16). Consistently, AUC24h < 50 mg·h/L was defined as underexposure, AUC24h 164 
between 50 and 160 mg·h/L was defined as optimal target exposure, and AUC24h > 160 mg·h/L was 165 
defined as overexposure. Permissible doses were defined as those producing a less than 10% of 166 
probability of causing both drug underexposure and overexposure in each class of renal function. 167 
The identified levofloxacin doses were considered sufficiently safe for clinical use in this 168 
population, and were subsequently tested in the pharmacokinetic/pharmacodynamic analysis.  169 
 170 
Pharmacokinetic/pharmacodynamic (PK/PD) analysis 171 
AUC24h/MIC ratios were calculated for all of those patients who had bacterial clinical 172 
isolates yielded and tested for levofloxacin susceptibility. Considering that levofloxacin is 173 
approximately 30% plasma protein bound, all the pharmacodynamic targets were multiplied by 174 
factor 0.7 in order to obtain the free targets (fAUC24h/MIC), which were than included in the PK/PD 175 
analysis.  176 
Logistic regression analysis was used to explore the relationship between drug exposure and 177 
other clinical factors on the probability of clinical outcome. For those patients who had 178 
antimicrobial combination therapy, we created a dichotomous categorical variable. Covariates 179 
resulting with a P < 0.20 at the univariate analysis were deemed of potential clinical relevance and 180 
then included in the multivariate model on the basis of a forwards stepwise approach.  181 
Classification and regression tree (CART) analysis was used to develop a prediction model 182 
for detecting the cut-off value of AUC24h/MIC ratio that best correlates with favorable clinical 183 
outcome in the study population. Subsequently, the validity of the identified cut-off value was 184 
tested by means of receiver operating characteristic (ROC) analysis.  185 
 186 
Probability of target attainment (PTA) and cumulative fraction of response (CFR) at the cut-off 187 
AUC24h/MIC ratio associated with favorable clinical outcome  188 
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We estimated the probability of target attainment (PTA) of the identified cut-off value of 189 
AUC24h/MIC ratio in relation to the various levofloxacin doses.  The cumulative fraction of 190 
response (CFR)(21) was then assessed against those bacterial species that were more frequently 191 
isolated in the study population.   Optimal CFR was defined as ≥ 80 % of subjects within the 192 
desired AUC24h/MIC range. 193 
 194 
Statistical analysis 195 
The Kolmogorov–Smirnov test was used to assess whether data were normally or non-196 
normally distributed. Accordingly, the mean+SD or median with IQR were used in the descriptive 197 
statistics.  Categorical variables were compared by the χ2 test or Fisher’s exact test, while 198 
continuous variables were compared using the Student’s t-test or Mann–Whitney test. A P value < 199 
0.05 was required to achieve statistical significance. All statistical analysis were performed using 200 
Systat version 13 (Systat Software, Inc., USA).  201 
202 
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Results 203 
Patients characteristics 204 
One-hundred and sixty height acutely hospitalized older patients were included in this study. 205 
Demographic and clinical data are summarized in Table 1. The majority of patients were males 206 
(103/168, 61.3%), and the median (IQR) age of the study population was of 81 years (76 - 88). 207 
Community acquired pneumonia, urinary tract infections and acute exacerbation of chronic 208 
bronchitis accounted for most of the bacterial infections requiring levofloxacin treatments (118/168, 209 
70.2%). Levofloxacin was administered mainly orally (145/168, 86.3%) for a median length of 210 
treatment of 10 days. Favorable clinical outcome was reported in 73.2% of cases (123/168).  211 
 212 
Population pharmacokinetic analysis  213 
A total of 569 levofloxacin plasma concentrations (330 trough and 239 peak concentrations) 214 
were included in the population analysis. A two-compartment linear model, with first-order input 215 
(for orally administered doses) and first-order clearance from the central compartment, best 216 
described levofloxacin concentrations. Compartments were connected by first order inter-217 
compartmental rate constants. 218 
The only covariate that improved the model fit was CrCLCKD-EPI (OFV reduction from 2125 219 
to 2086; p < 0.01). The final model for clearance was as follows:  220 
Levofloxacin CL = 0.399 + 0.051∙CrCLCKD-EPI 221 
where: CL is the value of levofloxacin clearance and CrCLCKD-EPI is the estimated creatinine 222 
clearance by means of the CKD-EPI formula.     223 
Fig. 1 shows the diagnostic plots for the final covariate model. After MAP-Bayesian 224 
estimation, the observed versus predicted plot had an intercept and slope that were close to zero and 225 
1, respectively [Observed = 0.146 + 0.973∙Predicted (r2 = 0.905; p < 0.01)]. Bias and precision were 226 
acceptable (0.064 mg/L for bias and 1.64 mg/L for precision).  227 
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The mean (± SD) and the median pharmacokinetic parameter estimates for the final 228 
covariate model are shown in Table 2.  The distribution of the observed concentrations was 229 
consistent with that of the predicted concentrations, as suggested by the VPC plot (Fig. 2). The 230 
normal distribution of NPDEs (p = 0.115 at the Shapiro-Wilk for normality test) confirmed the 231 
adequacy of the model for dosing simulations. 232 
 233 
Monte Carlo simulation for estimation of levofloxacin doses predicting optimal target drug 234 
exposure in older patients with various degrees of renal function  235 
Table 3 shows the distributions of probabilities of simulated patients having underexposure, 236 
optimal target exposure and overexposure with the various permissible doses of levofloxacin.  The 237 
regimens that were associated with the highest proportion of optimal target exposure and lowest risk 238 
of under and/or overexposure were as follows: 500 mg every 48 h for CrCLCKD-EPI < 20 ml/min/1.73 239 
m2; 750 mg every 48 h for CrCLCKD-EPI of 20-39 ml/min/1.73 m2; 500 mg every 24 h for CrCLCKD-240 
EPI of 40-59 ml/min/1.73 m2; 750 mg every 24 h for CrCLCKD-EPI of 60-79 ml/min/1.73 m2 and 500 241 
mg every 12 h for CrCLCKD-EPI of > 80 ml/min/1.73 m2. Nevertheless, > 20% risk of underexposure 242 
could be expected when using 500 mg every 24 h or 750 mg every 24 h in patients with  CrCLCKD-243 
EPI of 40-59 and 60-79 ml/min/1.73 m2, respectively. Similarly, > 10%  risk of overexposure could 244 
be observed when using 500 mg every 48 h or 500 mg every 12 h in patients with  CrCLCKD-EPI of < 245 
20 and > 80 ml/min/1.73 m2, respectively.     246 
 247 
PK/PD analysis  248 
Forty-nine patients had documented bacterial infections, but only 41 out of them (83.7%) 249 
were eligible for the PK/PD analysis (4 had to be excluded because of infections caused by 250 
levofloxacin-resistant pathogens, 3 because of death for other causes and 1 because of stopping 251 
therapy for adverse events). Most of the eligible patients received levofloxacin as monotherapy 252 
(56.1%) and had favorable clinical outcome (75.6%).       253 
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Blood and urine accounted for most of the primary source of infection (80.5 %). The 254 
bacteria most frequently yielded were E. coli, S. aureus and P. aeruginosa, which accounted overall 255 
for 65.1% (28/43) of isolates (Table 4).  256 
The cut-off value of total AUC24h/MIC ratio identified as valuable predictor of favorable 257 
clinical outcome at CART analysis was of ≥ 95.7. Among the five patients whose AUC24h/MIC 258 
ratios were below this breakpoint, in only one case (1/5, 20%) a positive clinical outcome was 259 
observed. Conversely, of the thirt-six patients having  AUC24h/MIC ratios  ≥ 95.7, a positive clinical 260 
outcome was observed in thirty (30/36, 83.3%) cases. The area under the ROC curve for this cut-off 261 
value was high (0.79). 262 
Among the various covariates that were tested at the univariate analysis for potential 263 
relationship with favorable clinical outcome (age, gender, weight, CrCLCKD-EPI, route of 264 
levofloxacin administration, AUC24h/MIC ratio ≥ 95.7, length of levofloxacin treatment, co-265 
treatment with other antimicrobials), only weight (p = 0.117, log-likelihood = -21.399)  and 266 
AUC24h/MIC ratio ≥ 95.7 (p < 0.05, log-likelihood = -19.328) were predictive of a favorable clinical 267 
outcome.  At the multivariate logistic regression analysis, only AUC24h/MIC ratio ≥  95.7 was 268 
definitely associated with favorable clinical outcome (OR 20.85: 95% CI 1.56 – 186.73, p < 0.05, 269 
log-likelihood = -16.828).  270 
 271 
PTA and CFR at the cut off AUC24h/MIC ratio associated with favorable clinical outcome 272 
Fig. 3 shows the probability of achieving the AUC24h/MIC ratio cut-off value of ≥ 95.7 with 273 
the various permissible doses of levofloxacin. The analysis showed that the permissible 274 
levofloxacin doses may achieve optimal PTAs only against those pathogens with an MIC for 275 
levofloxacin of ≤ 0.5 mg/L.  276 
Table 5 summarizes the levofloxacin doses that resulted effective AUC24h s in older patients 277 
in relation to different degrees of susceptibility of the pathogens to levofloxacin.  278 
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Table 6 shows the CFR of the permissible doses of levofloxacin against the bacterial 279 
pathogens that were most frequently yielded in our study population (E. coli. S. aureus, H. 280 
influenzae and P. aeruginosa). Although optimal CFR were always achieved against S. aureus, H. 281 
influenzae and E.coli, this was never the case against P. aeruginosa. 282 
283 
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Discussion 284 
In this study we addressed the issue of dosing optimization with levofloxacin in acutely 285 
hospitalized older patients, among whom the attainment of optimal pharmacodynamic targets of 286 
efficacy with fluoroquinolones should be balanced against safety concerns.  287 
Population pharmacokinetic modeling provided robust estimates of the pharmacokinetic 288 
parameters in our population.  The final model explained almost 91% of the variability of drug 289 
concentrations over time, with acceptable bias and precision. The pharmacokinetic estimates of 290 
levofloxacin in the study population are quite different from those previously described in other 291 
cohorts. The mean CL of levofloxacin in our population was consistently lower (2.53 L/h)  than that 292 
observed among healthy volunteers (16), adult patients with normal renal function (8, 22, 23), and 293 
elderly patients with CAP (24).  Of note, this is in agreement with the fact that most of our patients, 294 
differently from those of the other studies, were very old (mean age 81.2 years) and had impaired 295 
renal function (median CrCLCKD-EPI of  30.4 mL/min/1.73 m2). 296 
The fact that CrCLCKD-EPI was the only covariate that improved model fit is similar to 297 
previous findings in elderly patients (25). This suggests that estimation of renal function by means 298 
of this formula should be considered mandatory in older patients for calculating appropriate dose 299 
adjustments of levofloxacin in order to avoid drug overexposure.  Interestingly, our Monte Carlo 300 
simulations provided a detailed stratification of dose adjustments of levofloxacin in relation to 301 
different levels of renal function in older patients. It is worth noting that in patients with severe 302 
renal impairment (CrCLCKD-EPI < 40 mL/min/1.73 m2), levofloxacin dosage must be more than 303 
halved in order to avoid overexposure.  304 
Our approach, by targeting in all of the patients drug exposure within a desired range similar 305 
to that observed in subjects with normal renal function, may minimize the risk of exposure-306 
dependent toxicity among older patients. This is in agreement with a recent Japanese study showing 307 
that adjustments of levofloxacin dose in relation to the degree of renal function may help in 308 
decreasing the incidence of adverse events in elderly patients (14). In this regard, it is worth 309 
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mentioning that among our study population no patients suffered from tendinopathy or had to stop 310 
therapy because of chondrotoxicity (data not shown). 311 
The opportunity of defining permissible doses of levofloxacin in older patients is furtherly 312 
strengthened by the findings of two recent reviews showing that levofloxacin is the fluoroquinolone 313 
associated with the highest risk of causing tendon damages (10, 12). This may furtherly strengthen 314 
the valuable role that a real-time TDM-guided approach of levofloxacin dosage adjustments may 315 
have in preventing drug-related toxicity in older patients.  316 
Our approach still ensured patients a high probability of having favorable clinical outcome. 317 
The relatively high cut-off value of AUC24h/MIC ratio identified by CART analysis as a valuable 318 
predictor of clinical efficacy among our study population (≥ 95.7) was similar to that reported 319 
previously by Drusano et al. among patients with nosocomial pneumonia (8). This might be 320 
explained by the fact that most of  the bacterial clinical isolates included in our analysis, similarly to 321 
what occurred in the Drusano’s one, were Gram-negative pathogens, which were shown to require 322 
much higher pharmacodynamic thresholds than Gram-positives.  323 
Importantly, our pharmacodynamic analyses suggested that pathogens with an MIC ≤ 0.5 324 
mg/L are adequately treated. However, even if this value is lower than the EUCAST clinical 325 
breakpoint of susceptibility of levofloxacin against Gram-negative and Gram-positive pathogens 326 
which is set to 1 mg/L,  it corresponds to that of USCAST for S. aureus and E. coli  (26). In both 327 
cases, this poses potential concerns about the efficacy of levofloxacin monotherapy in some 328 
settings.  Results similar to ours were reported in a population pharmacokinetic analysis of 38 adults 329 
Korean patients. In that study a levofloxacin  regimen of 250 and 500 mg once daily in patients with 330 
CrCL of 20-50 and > 50 mL/min, respectively, resulted in AUC24h/MIC ratio > 100 only against 331 
pathogens with an  MIC up to and including 0.5 mg/L (23).  Conversely, in another study it was 332 
shown that dosing regimens of  125, 250, and 500 mg once daily were predicted to ensure PTA > 333 
90% against pathogens with an MIC up to 2 mg/L in patients with CrCL < 20, 20-50 and > 50 334 
mL/min respectively (27). Besides, it is worth mentioning that our study is unique in that PTAs 335 
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were estimated for various doses of levofloxacin that were different in relation to various degrees of 336 
renal function. This step, in our opinion, should be considered mandatory nowadays in order to 337 
prevent exposure-related toxicity with levofloxacin in older patients (12).  338 
When looking at species-specific CFR, optimal CFR in older patients may be predicted in 339 
relation to the permissible doses against E. coli and H. influenzae, whereas borderline CFR  may be 340 
achieved against S. aureus. This offers the opportunity to speculate that levofloxacin may still 341 
represent a valuable therapeutic weapon in older patients for the treatment of urinary tract 342 
infections, which are frequently caused by E. coli. Similarly, levofloxacin may be valuable in the 343 
treatment of hematogenous discitis, which may be frequently caused by methicillin-susceptible S. 344 
aureus.  Conversely, only suboptimal CFR were observed against P. aeruginosa, and this means 345 
that nowadays levofloxacin should not be considered as effective anti-pseudomonal monotherapy.   346 
This study has several limitations. The retrospective design, the lack of evaluation of 347 
microbiological eradication in assessing clinical outcome and the use of combination antimicrobial 348 
therapy are all relevant considerations. As far as the population analysis is concerned, we recognize 349 
that estimate of ka might not be robustly enough, due to the limited variability in sampling time of 350 
peak concentrations. Additionally, we recognize that our definition of overexposure is arbitrary, but 351 
we strongly believe that this approach may be helpful in containing the risk of exposure-dependent 352 
toxicity with levofloxacin. Finally, we acknowledge that our PK/PD analysis was based mainly on 353 
Gram-negatives pathogens, and this could mean that the identified cut-off AUC24h/MIC target is 354 
probably too high for S. pneumoniae, a pathogen for which an AUC24h/MIC > 30 is commonly 355 
accepted as pharmacodynamic target of efficacy.  Nevertheless, the large patient sample size and the 356 
heterogeneity of patients’ diagnosis could strengthen the generalizability of our results.  357 
In conclusion, our study is unique in that it defined for the first time the permissible doses of 358 
levofloxacin that should be administered in older patients with various degrees of renal function in 359 
order to minimize the risk of exposure-dependent toxicity.  Additionally, it highlights that these 360 
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doses might be effective only when treating infections due to bacterial pathogens with an MIC ≤ 0.5 361 
mg/L, which could have implications for in vivo susceptibility clinical breakpoints.  362 
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 451 
Figure Legends: 452 
 453 
FIG 1 Diagnostic plot for the final covariate model. Observed versus population predicted plasma 454 
concentrations (left panel) and individual predicted plasma concentrations (right panel) in plasma.  455 
 456 
FIG 2 Visual predictive check of levofloxacin plasma concentrations versus time for the final 457 
covariate model. 458 
 459 
FIG 3 Probability of achieving and AUC24h/MIC value of ≥ 95.7 with the various permissible doses 460 
of levofloxacin in relation to different degrees of renal function and of  susceptibility of the 461 
invading pathogen.  462 
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Table 1. Population characteristics  
Patients’ demographics  
 Age (years), mean ± SD 81.2 ± 7.8 
 Gender (male/female), n (%) 103/65 (61.3/38.7) 
 Body weight (kg), median (IQR) 70 (65 - 80) 
 CrCLCKD-EPI (ml/min/1.73 m2)a, median (IQR) 30.2 (18.2 - 50.2) 
Indication for levofloxacin use, n (%)   
 Community acquired pneumonia  77 (45.8) 
 Urinary tract infections 22 (13.1) 
 Chronic obstructive pulmonary disease 19 (11.3) 
 Fever of unknown origin 12 (7.1) 
 Sepsis of unknown origin 13 (7.7) 
 Intra-abdominal infections 11 (6.6) 
 Skin and soft tissue infections 8 (4.8) 
 Bone and joint infections 6 (3.6) 
Patients with identified microbiological isolates, n (%) 49 (29.2) 
Levofloxacin treatment   
 Duration of therapy (days), median (IQR) 10 (7-14) 
 Route of administration (oral/i.v.), n (%) 145/23 (86.3/13.7) 
Clinical outcome, n (%)  
 Cured 95 (56.5) 
 Improved 28 (16.7) 
 Failed 26 (15.5) 
 Dead/modified antibiotic therapy  19 (11.3) 
a at first TDM 
CrCLCKD-EPI, creatinine clearance estimated by means of the CKD-EPI formula; i.v., intravenous route of 
administration; oral, oral route of administration; IQR, interquartile range; SD, standard deviation 
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Table 2. Parameter estimates for final population pharmacokinetic model of levofloxacin in older patients 
Unit ka (h-1) kcp (h-1) kpc (h-1) CL (L/h) Vc (L) Fos (%) Tlag (h) 
Mean 16.15 0.63 1.77 2.53 52.95 0.83 1.47 
Standard deviation 13.47 0.85 0.52 1.46 21.57 0.21 0.65 
Coefficient of variation 83.41 133.52 29.47 57.84 40.73 24.83 43.95 
Median 9.91 0.04 2.00 2.20 61.25 0.98 1.87 
CL, total clearance of levofloxacin; ka, first-order transfer rate constant of absorption; kcp and kpc, first-order intercompartmental transfer arte 
constant connecting the central and peripheral compartments; Fos, oral bioavailability of levofloxacin; Tlag, time delay between drug 
administration and first observed concentration; Vc, volume of the central compartment. 
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Table 3. Probability of achieving underexposure (AUC24h < 50 mg·h/L), normal target exposure (AUC24h between  50-160 mg·h/L) and overexposure (AUC24h > 160 
mg·h/L) with different levofloxacin dosing regimens in older patients in relation to different classes of renal function.  
Levofloxacin 
regimens 
Classes of renal function (mL/min/1.73 m2)  
and of levofloxacin AUC24h (mg∙h/L) 
  0-19    20-39    40-59    60-79    > 80  
 <50 50-160 >160  <50 50-160 >160  <50 50-160 >160  <50 50-160 >160  <50 50-160 >160 
125 mg 48-hourly 91.8 8.2 0.0  99.8 0.2 0.0  99.8 0.2 0.0  99.9 0.1 0.0  100.0 0.0 0.0 
250 mg 48-hourly 48.5 50.5 1.0  91.4 8.6 0.0  99.0 1.0 0.0  99.6 0.4 0.0  99.9 0.1 0.0 
500 mg 48-hourly 6.4 77.2 16.4  32.2 67.0 0.8  81.6 18.4 0.0  95.7 4.3 0.0  97.2 2.8 0.0 
750 mg 48-hourly 1.4 53.9 44.7  7.2 86.2 6.6  42.2 57.2 0.6  79.6 20.0 0.4  89.0 11.0 0.0 
500 mg 24-hourly 2.3 50.3 47.4  5 81.3 13.7  22.2 76.0 1.8  59.2 40.1 0.7  78.7 21.0 0.3 
750 mg 24-hourly 1.1 17.1 81.8  1.7 51.3 47.0  5.8 82.8 11.4  23.1 73.1 3.7  50.3 47.6 2.1 
500 mg 12-hourly 3.3 3.6 99.7  0.2 12.3 87.5  0.1 39.0 60.9  1.5 70.1 28.4  2.8 82.8 14.4 
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Table 4. Bacterial pathogens (n = 43 yielded from 41 patients) included in the 
pharmacokinetic/pharmacodynamic analysis  
Pathogen No. of isolates MIC range 
 (mg/L) 
Escherichia coli 12 0.03 - 4 
Staphylococcus aureus 9 0.125 - 0.5 
Pseudomonas aeruginosa 7 0.25 - 2 
Klebsiella pneumoniae 4 0.06 - 1 
Haemophilus influenzae 2 0.03 
Klebsiella oxytoca 2 0.06 - 1 
Staphylococcus epidermidis  2 0.25 - 4 
Enterobacter aerogenes 1 0.125 
Streptococcus pneumoniae 1 1 
Staphylococcus saprofiticus 1 0.5 
Staphylococcus schleiferi 1 0.25 
Staphylococcus capitis 1 0.25 
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Table 5. Permissible dosing regimens of levofloxacin  granting optimal PTA in older patients in relation to different degrees of renal function and of 
the susceptibility of the invading bacterial pathogen 
MICs 
(mg/L) 
Classes of renal function 
(mL/min/1.73 m2) 
 0-19  20-39  40-59  60-79  > 80  
0.125 125 mg every 48h 500 mg every 48h 500 mg every 48h 500 mg every 48h 750 mg every 48h 
0.25 250 mg every 48h 500 mg every 48h 500 mg every 48h 750 mg every 48h 750 mg every 24h 
0.5 500 mg every 48h 750 mg every 48h 500 mg every 24h 750 mg every 24h 500 mg every 12h 
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Table 6. Cumulative fraction of response of the permissible doses of levofloxacin against the 
invading pathogens more frequently yielded in the study population according to their EUCAST MIC 
distribution  
Classes of renal function 
(mL/min/1.73 m2) 
Levofloxacin doses SA HI EC PA 
0-19 125 mg every 48h 59.89 99.66 82.06 16.48 
 250 mg every 48h 77.03 99.78 85.07 40.36 
 500 mg every 48h 81.59 99.85 87.34 62.24 
20-39 500 mg every 48h 79.22 99.79 85.80 47.07 
 750 mg every 48h 81.26 99.84 87.12 59.63 
 500 mg every 24h 81.49 99.85 87.43 63.08 
40-59 500 mg every 48h 71.28 99.73 83.45 25.81 
 750 mg every 48h 77.73 99.78 85.26 42.03 
 500 mg every 24h 79.42 99.81 86.16 50.72 
 750 mg every 24h 81.13 99.84 87.28 61.63 
60-79 500 mg every 48h 57.19 99.65 81.57 14.41 
 750 mg every 48h 70.61 99.73 83.52 26.68 
 500 mg every 24h 74.86 99.76 84.55 36.08 
 750 mg every 24h 79.16 99.81 86.20 51.22 
>80 750 mg every 48h 60.72 99.67 82.12 18.21 
 500 mg every 24h 67.91 99.71 83.27 25.50 
 750 mg every 24h 75.51 99.77 84.90 39.43 
 500 mg every 12h 81.67 99.85 87.52 63.81 
SA, S. aureus; HI, H. influenzae; EC, E. coli; PA, P. aeruginosa 
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